A Phase 3 interventional study of Plozasiran Injection and Placebo in Hypertriglyceridemia, sponsored by Arrowhead Pharmaceuticals. Completed at 235 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Arrowhead Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 150 studies in Hypertriglyceridemia with a site in United States — 10 open to participants now, 16 under way, 4 of them phase 3. Hypertriglyceridemia · United States.
Among the 150 studies in Hypertriglyceridemia with a site in United States, this one is the 3rd largest by enrollment of the 145 interventional ones that give a count, is one of 7 that started in 2024, is one of 27 in phase 3, and was the 136th registered.
324 studies on the registry are indexed under Hypertriglyceridemia; 38 are open to participants now.
Browse Hypertriglyceridemia studies →10 of the 150 studies in Hypertriglyceridemia with a site in United States are open now. Recruiting first, the newest first:
Ionis Pharmaceuticals, Inc. · Sites in United States, Canada
Ages 18+
Eli Lilly and Company · Sites in United States, Canada, China and 1 more country
Ages 18+
Marea Therapeutics · Sites in United States
Ages 18–75
The Miriam Hospital · Sites in United States
Ages 18–69
Marea Therapeutics · Sites in United States, Australia, Canada and 1 more country
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 22 Hypertriglyceridemia studies recruiting now, 9 (41%) set no upper age limit and 12 (55%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
150 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 51 · Phase 3 30 · Phase 4 13
First in 1977; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,456 is above the median of 66 across 288 interventional studies indexed under Hypertriglyceridemia.
Median enrollment 52 across the 145 interventional studies, 130 across the 3 observational. Of the 124 that completed or were terminated, 57 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
74 of 150 have an industry lead sponsor. The 10 most frequent:
Arrowhead Pharmaceuticals is the lead sponsor of 50 studies on the registry; 9 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 12 (50%) have results posted.
Arrowhead Pharmaceuticals has 8 studies filed under Hypertriglyceridemia — fewer than ten, so there is no comparison to draw.
9 of the studies in Hypertriglyceridemia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05681351Phase 3Ionis Pharmaceuticals, Inc.CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) | 2027-03 |
| NCT02262832Phase 3National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy | 2027-07-31 |
| NCT05464784MediciNovaMN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia | 2026-12-31 |
| NCT07269210Eli Lilly and CompanyA Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia | 2027-03 |
| NCT07491172CRISPR Therapeutics AGA Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias | 2027-06 |
Add all 9 to your calendar (.ics) → With an account.
Among the 150 studies in Hypertriglyceridemia with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo and be evaluated for efficacy and safety.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Additional Inclusion/Exclusion criteria may apply per protocol
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
4 doses of plozasiran by subcutaneous (sc) injection
Drug: Plozasiran Injection
calculated volume to match active treatment by sc injection
Drug: Placebo
ARO-APOC3 Injection
Also known as: ARO-APOC3
sterile normal saline (0.9% NaCl)
Percent Change in Fasting Serum Triglyceride (TG) Levels from Baseline to Month 12 Compared to Placebo
Time frame: Baseline, Month 12
Percent Change in Fasting Serum TG Levels from Baseline to Month 10 Compared to Placebo
Time frame: Baseline, Month 10
Proportion of Participants who Achieve Fasting TG Levels of <150 mg/dL (<1.69 mmol/L) at Month 12 Compared to Placebo
Time frame: Month 12
Percent change in remnant cholesterol (VLDL-C) from baseline to Month 12 compared to placebo.
Time frame: Baseline, Month 12
Percent change in non-HDL-C from baseline to Month 12 compared to placebo
Time frame: Baseline, Month 12
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) Over Time through Month 12 as Compared to Placebo
Time frame: From first dose of study drug through Month 12
Incidence Rates of New-Onset Diabetes Mellitus (NODM) Throughout the Course of Treatment
Time frame: From first dose of study drug through Month 12
Incidence Rates of Impaired Glucose Tolerance Throughout the Course of Treatment
Time frame: From first dose of study drug through Month 12
Incidence Rates of Worsening of Existing Diabetes Throughout the Course of Treatment
Time frame: From first dose of study drug through Month 12
Change from Baseline in Hemoglobin A1c (HbA1c) and Other Glycemic Control Parameters During the Treatment Period Compared to Placebo
Time frame: From first dose of study drug through Month 12
Change from Baseline in Fasting Blood Glucose During the Treatment Period Compared to Placebo
Time frame: From first dose of study drug through Month 12
Change from Baseline in C-peptide During the Treatment Period Compared to Placebo
Time frame: From first dose of study drug through Month 12
Change from Baseline in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) During the Treatment Period Compared to Placebo
Time frame: From first dose of study drug through Month 12
Change from Baseline in Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related Adverse Events (TRAEs) Associated with Worsening Glycemic Control During the Treatment Period Compared to Placebo
Time frame: From first dose of study drug through Month 12
Initiation of New Medication for Hyperglycemia Among Study Participants Not Known to Have Pre-existing Diabetes Mellitus During the Treatment Period Compared to Placebo
Time frame: From first dose of study drug through Month 12
Adjudicated Major Adverse Cardiovascular Events (MACE) Rates During the Treatment Period Compared to Placebo
Time frame: From first dose of study drug through Month 12
Incidence of Anti-drug Antibodies (ADA) to Plozasiran in Participants Receiving Plozasiran Over Time Through Month 12
Time frame: From first dose of study drug through Month 12
Titers of Anti-drug Antibodies (ADA) to Plozasiran in Participants Receiving Plozasiran Over Time Through Month 12
Time frame: From first dose of study drug through Month 12
Showing the first 100 of 235 sites across 15 countries. Choose a country and city above to see the rest.
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2024 to primary completion in Jun 2026, 24 months.
Of 28 industry-sponsored phase 3 interventional studies under Hypertriglyceridemia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 31. This study's 24 months is close to that.
Counting every sponsor, half of 29 studies reached it within 24 months; a quarter within 18 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Plozasiran